~~<i id='F67F99A6E0'><strike id='F67F99A6E0'><tt id='F67F99A6E0'><pre id='F67F99A6E0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：Wikipedia 2025-10-01 01:00:37 - browse：76779

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Eli Lilly said Tuesday that it will purchase DICE Therapeutics, a small company developing an experimental pill to treat psoriasis, for $2.4 billion in cash.

The deal price of $48 per share represents a 42% premium to DICE’s closing price Friday.

“In combination with its novel technology and expertise in drug discovery, DICE’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases,” Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, chief customer officer, said in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： As JPM 2024 winds down, some health tech firms project optimism

hotspot

focus

knowledge

hotspot

focus

hotspot

AdobeScientistsaretaughtearlyinourtrainingthatcriticismisafundamentalpartofthejob.Whatwearenotusuall

WSS

Medicare coverage of Wegovy, once blocked, now looks possible

Doulas covered by Medicaid under New York's new plan

Steward Health Care Massachusetts hospitals face fiscal disaster

First U.S. drug developed to treat liver disease MASH is approved

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

explore

entertainment

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: CAR

After affirmative action ruling, medical educators look to 'holistic review'

Boston's new lab space is opening empty

After affirmative action ruling, medical educators look to 'holistic review'

HHS secretary Becerra pressed on Change HealthCare cyberattack

Trump demands the U.S. pay no more for drugs than other countries … again

Change Healthcare outage fallout shows need for new oversight

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Fauci’s Covid grilling leads GOP to weigh foreign research rules

focus

HHS names first

President Biden's budget: Here's what you might have missed

First U.S. drug developed to treat liver disease MASH is approved

Readout LOUD podcast: live from JPM 2024

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

knowledge

hotspot

focus

hotspot